Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is reporting third quarter earnings results on Tuesday 10th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.07 per share from $ 8.61 million in revenue.
For the full year, analysts predict revenues of $ 38.28 million, while looking forward to income of $ 0.09 per share.
Previous Quarter Performance
Cumberland Pharmaceuticals Inc. disclosed income for the second quarter of $ 0.08 per share, from the revenue of $ 9.60 million. The quarterly earnings shrunk 20.00 percent compared with the same quarter last year. Wall street analysts are predicting, CPIX to report 2Q20 income of $ 0.03 per share from revenue of $ 9.27 million. The bottom line results beat street analysts by $ 0.05 or 166.67 percent, at the same time, top line results outshined analysts by $ 0.33 million or 3.56 percent.
Stock Performance
Shares of Cumberland Pharmaceuticals Inc. traded up $ 0.07 or 2.40 percent on Monday, reaching $ 2.99 with volume of 31.30 thousand shares. Cumberland Pharmaceuticals Inc. has traded high as $ 3.07 and has cracked $ 2.94 on the downward trend
According to the previous trading day, closing price of $ 2.99, representing a 5.42 % increase from the 52 week low of $ 2.77 and a 49.66 % decrease over the 52 week high of $ 5.80.
The company has a market capital of $ 45.26 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Cumberland Pharmaceuticals Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.cumberlandpharma.com
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The companys Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.
